This includes interim data from its expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib. This seeks to use this drug combination to treat patients suffering from ER+ metastatic breast cancer (mBC).
EFFECTOR Therapeutics notes that of the 19 patients in the study, five have seen a partial response. That includes four confirmed and one unconfirmed. This positive data is exciting investors as it means there’s potential for EFTR’s treatment to get further trials.
Doug Warner, M.D., chief medical officer of eFFECTOR Therapeutics, said the following about the clinical trial results:
“I am excited about the early efficacy and safety results of the novel therapeutic candidate zotatifin and look forward to continuing its development in patients with advanced ER+ breast cancer who are currently medically underserved.”
What This Means for EFTR Stock
Today’s news markets another step forward for eFFECTOR Therapeutics and its development of zotatifin. If it can keep this up, there’s potential for a commercial release of the mBC treatment. That would bring with it a new source of revenue for the company.
The idea of this has EFTR stock climbing higher with heavy trading today. As of this writing, more than 4.7 million shares of the stock have changed hands. That’s well above its daily average trading volume of about 255,000 shares.
EFTR stock is up 74.8% as of Friday morning.
There’s more stock market news traders can read about below!
We’ve got all of the latest stock market coverage traders need to know about on Friday! Among that is what’s moving shares of Appreciate Holdings (NASDAQ:SFR) stock, the biggest pre-market stock movers, and more. All of that news is ready to go with the following links!
More Friday Stock Market News
- Why Is Appreciate (SFR) Stock Up 95% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- Will Carl Icahn Step in to Save Bed Bath & Beyond (BBBYQ) Stock?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.